mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients

Clinical Cancer Research

Volumn 17, Issue 11, 2011, Pages 3600-3618

  Sieuwerts, Anieta M ^a   Mostert, Bianca ^b   Bolt De Vries, Joan ^a   Peeters, Dieter ^e   De Jongh, Felix E ^c   Stouthard, Jacqueline M L ^d   Dirix, Luc Y ^e   Van Dam, Peter A ^e   Van Galen, Anne ^a   De Weerd, Vanja ^a   Kraan, Jaco ^b   Van Der Spoel, Petra ^b   Ramírez Moreno, Raquel ^f   Van Deurzen, Carolien H M ^a   Smid, Marcel ^a   Yu, Jack X ^g   Jiang, John ^g   Wang, Yixin ^g   Gratama, Jan W ^b   Sleijfer, Stefan ^b   Foekens, John A ^a   Martens, John W M ^a   more..

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c IKAZIA HOSPITAL   (Netherlands)

^d Maasstad Hospital Rotterdam   (Netherlands)

^e ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^f UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^g Veridex LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; MESSENGER RNA; MICRORNA;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CELL COUNT; CELL ISOLATION; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; CELL ADHESION MOLECULES; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LEUKOCYTES; MICRORNAS; NEOPLASM METASTASIS; NEOPLASTIC CELLS, CIRCULATING; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79957894183     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0255     Document Type: Article

References (52)

1. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
2. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-9. (Pubitemid 44200649)
3. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128: 683-92. (Pubitemid 46273572)
4. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008;452: 564-70.
5. Esteller M. Epigenetics in cancer. N Engl J Med 2008;358:1148-59.
6. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10:389-402.
7. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49. (Pubitemid 36808649)
8. Mimori K, Kataoka A, Yoshinaga K, Ohta M, Sagara Y, Yoshikawa Y, et al. Identification of molecular markers for metastasis-related genes in primary breast cancer cells. Clin Exp Metastasis 2005;22:59-67. (Pubitemid 41185862)
9. Suzuki M, Tarin D. Gene expression profiling of human lymph node metastases and matched primary breast carcinomas: clinical implications. Mol Oncol 2007;1:172-80. (Pubitemid 47199131)
10. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol 2009;4:809-15.
11. Cavalli LR. Molecular markers of breast axillary lymph node metastasis. Expert Rev Mol Diagn 2009;9:441-54.
12. Gevaert O, Daemen A, De Moor B, Libbrecht L. A taxonomy of epithelial human cancer and their metastases. BMC Med Genomics 2009;2:1-16.
13. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-13.
14. Food and Drug Administration HHS. Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist 2004;69:26036-8.
15. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, et al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007;13:7053-8. (Pubitemid 350276887)
16. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006;6:125-32. (Pubitemid 44445747)
17. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91. (Pubitemid 39095313)
18. Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex realtime PCR. Breast Cancer Res Treat 2009;118:455-68.
19. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, et al. Combinatorial microRNA target predictions. Nat Genet 2005;37: 495-500. (Pubitemid 40617277)
20. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005;122:6-7. (Pubitemid 40977933)
21. Foekens JA, Sieuwerts AM, Smid M, Look MP, de Weerd V, Boersma AW, et al. Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A 2008;105:13021-6.
22. Bartels CL, Tsongalis GJ. MicroRNAs:novel biomarkers for human cancer. Clin Chem 2009;55:623-31.
23. Tong AW, Nemunaitis J. Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther 2008;15:341-55.
24. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, et al. Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006;12:6403-9. (Pubitemid 44799711)
25. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006;12:4218-24.
26. Cristofanilli M, Broglio KR, Guarneri V, Jackson S, Fritsche HA, Islam R, et al. Circulating tumor cells in metastatic breast cancer:biologic staging beyond tumor burden. Clin Breast Cancer 2007;7:471-9. (Pubitemid 46424284)
27. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101:61-6.
28. Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011;127:33-41.
29. Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, et al. How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 2005;11:7311-21. (Pubitemid 41507689)
30. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, et al. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14:1340-8. (Pubitemid 351413913)
31. Mestdagh P, Van Vlierberghe P, De Weer A, Muth D, Westermann F, Speleman F, et al. A novel and universal method for microRNA RTqPCR data normalization. Genome Biol 2009;10:R64.
32. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995;57:289-300.
33. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8. (Pubitemid 29003722)
34. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4:P3.
35. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009;4:44-57.
36. Shi W, de Graaf CA, Kinkel SA, Achtman AH, Baldwin T, Schofield L, et al. Estimating the proportion of microarray probes expressed in an RNA sample. Nucleic Acids Res 2010;38:2168-76.
37. Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, et al. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res Treat 2009;121:53-64.
38. Mehes G, Witt A, Kubista E, Ambros PF. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001;159:17-20. (Pubitemid 33704186)
39. Alix-Panabières C, Brouillet JP, Fabbro M, Yssel H, Rousset T, Maudelonde T, et al. Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients. J Immunol Methods 2005;299:177-88. (Pubitemid 40725934)
40. Tewes M, Aktas B, Welt A, Mueller S, Hauch S, Kimmig R, et al. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009;115:581-90.
41. Fehm T, Hoffmann O, Aktas B, Becker S, Solomayer EF, Wallwiener D, et al. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells. Breast Cancer Res 2009;11:R59.
42. Bölke E, Orth K, Gerber PA, Lammering G, Mota R, Peiper M, et al. Gene expression of circulating tumour cells in breast cancer patients. Eur J Med Res 2009;14:426-32.
43. Wang HY, Cheng Z, Malbon CC. Overexpression of mitogen-activated protein kinase phosphatases MKP1, MKP2 in human breast cancer. Cancer Lett 2003;191:229-37. (Pubitemid 36255609)
44. Cariati M, Naderi A, Brown JP, Smalley MJ, Pinder SE, Caldas C, et al. Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line. Int J Cancer 2008;122:298-304. (Pubitemid 350234715)
45. Flores LM, Kindelberger DW, Ligon AH, Capelletti M, Fiorentino M, Loda M, et al. Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer. Br J Cancer 2010;102:1495-502.
46. Cho WC. MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42: 1273-81.
47. Schwartz LH, Koerner FC, Edgerton SM, Sawicka JM, Rio MC, Bellocq JP, et al. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 1991;51: 624-8.
48. Gradilone A, Naso G, Raimondi C, Cortesi E, Gandini O, Vincenzi B, et al. Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance and phenotypic characterization. Ann Oncol 2011;22:86-92.
49. Pestrin M, Bessi S, Galardi F, Truglia M, Biggeri A, Biagioni C, et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat 2009;118:523-30.
50. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast 2009;18 Suppl 3:S38-40.
51. Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, et al. Receptor conversion in distant breast cancer metastases. Breast Cancer Res 2010;12:R75.
52. O'Malley FP. Lobular neoplasia: morphology, biological potential and management in core biopsies. Mod Pathol 2010;23 Suppl 2:S14-25.